Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.
PER Pulse™ Recap
highlights key points presented at the Oncology Nurses Society (ONS) 41st Annual Congress, San Antonio Texas.
This activity is supported by educational grants from Helsinn Therapeutics (US), Inc. and TESARO.
Chemotherapy-induced nausea and vomiting (CINV) has far-reaching effects. CINV impairs quality of life, negatively impacts nutritional status, interferes with chemotherapy treatment, elevates the risk of nonadherence to chemotherapy, and increases the use of health care resources. Therapeutic advances in this field have resulted in a better understanding of CINV pathophysiology, and personalizing therapy for CINV according to patient risk factors and chemotherapy regimens. New antiemetic agents address some of the major unmet clinical needs in preventing and treating CINV, and it is critical for practitioners to understand novel mechanisms of action for these therapies and apply practice-changing evidence and guidelines to optimize care. For this activity, we are bringing together a panel of internationally recognized experts in the field to discuss how we can advance the care of these patients at risk for CINV.
Instructions For This Activity & Receiving Credit
This educational activity is directed toward nurses and other health care professionals involved in the treatment of cancer patients, both at risk for and experiencing CINV.
Richard J. Gralla, MD, FACP
Professor of Medicine
Albert Einstein College of Medicine
Jacobi Medical Center
Disclosure: Consultant: Merck, Tesaro, Helsinn, Eisai; Other Support: Honoraria: Merck, Helsinn, Eisai.
Rebecca Clark-Snow, RN, BSN, OCN
Clinical Nurse Coordinator
The University of Kansas Cancer Center
Disclosure: No relevant financial relationships with commercial interests.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with commercial interests.
It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell Tumors
Apr 28, 2018
April 28, 2018
New York, NY